Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Front Cell Infect Microbiol ; 11: 785157, 2021.
Article in English | MEDLINE | ID: mdl-35145921

ABSTRACT

With population genetic evidence of recombination ongoing in the natural Aspergillus fumigatus population and a sexual cycle demonstrated in the laboratory the question remained what the natural niche for A. fumigatus sex is. Composting plant-waste material is a known substrate of A. fumigatus to thrive and withstand temperatures even up to 70°C. Previous studies have shown indirect evidence for sexual reproduction in these heaps but never directly demonstrated the sexual structures due to technical limitations. Here, we show that flower bulb waste material from stockpiles undergoing composting can provide the conditions for sexual reproduction. Direct detection of ascospore structures was shown in agricultural flower bulb waste material by using a grid-based detection assay. Furthermore, we demonstrate that ascospores can germinate after exposure to 70°C for up to several days in contrast to asexual conidia that are unable to survive a two-hour heat shock. This indicates a sufficient time frame for ascospores to survive and escape composting stockpiles. Finally, sexual crosses with cleistothecium and viable ascospore formation could successfully be performed on flower bulb waste material. Recombination of A. fumigatus can now be explained by active sexual reproduction in nature as we show in this study that flower bulb waste material provides an environmental niche for sex.


Subject(s)
Aspergillus fumigatus , Reproduction , Aspergillus fumigatus/genetics , Flowers , Plant Roots , Spores, Fungal/genetics
2.
Emerg Infect Dis ; 25(7): 1347-1353, 2019 07.
Article in English | MEDLINE | ID: mdl-31211684

ABSTRACT

Azole resistance is a major concern for treatment of infections with Aspergillus fumigatus. Environmental resistance selection is a main route for Aspergillus spp. to acquire azole resistance. We investigated the presence of environmental hotspots for resistance selection in the Netherlands on the basis of the ability of A. fumigatus to grow and reproduce in the presence of azole fungicide residues. We identified 3 hotspots: flower bulb waste, green waste material, and wood chippings. We recovered azole-resistant A. fumigatus from these sites; all fungi contained cyp51A tandem repeat-mediated resistance mechanisms identical to those found in clinical isolates. Tebuconazole, epoxiconazole, and prothioconazole were the most frequently found fungicide residues. Stockpiles of plant waste contained the highest levels of azole-resistant A. fumigatus, and active aerobic composting reduced Aspergillus colony counts. Preventing plant waste stockpiling or creating unfavorable conditions for A. fumigatus to grow in stockpiles might reduce environmental resistance burden.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Drug Resistance, Fungal , Environmental Microbiology , Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus fumigatus/classification , Aspergillus fumigatus/genetics , Aspergillus fumigatus/isolation & purification , Azoles/therapeutic use , Genes, Bacterial , Humans , Microbial Sensitivity Tests , Netherlands/epidemiology
3.
J Fish Dis ; 42(6): 947-957, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30977527

ABSTRACT

Necropsy examination of an adult Atlantic salmon (Salmo salar) from the Dalälven River in Sweden revealed numerous large, white nodules, with spherical cysts and granulomata in kidney and liver. Histopathology showed dark, septate, thin-walled hyphae. The aetiologic agent was found to be an Ochroconis species (Venturiales) that differed from known fish-associated species of the genus. Molecular phylogenetic studies of the culture (strain UIII09 = CBS 135766) demonstrated that Ochroconis globalis was concerned. The isolate proved to be susceptible to all investigated antifungals, as it is known for another Ochroconis species. The role of Ochroconis in opportunism of cold-blooded animals was discussed, and the diagnostic methods using DNA sequences for routine identification of the fungus were proposed.


Subject(s)
Ascomycota/genetics , Fish Diseases/microbiology , Mycoses/veterinary , Salmo salar/microbiology , Animals , Antifungal Agents/pharmacology , Ascomycota/drug effects , Female , Fish Diseases/diagnosis , Hyphae/genetics , Hyphae/isolation & purification , Kidney/microbiology , Kidney/pathology , Liver/microbiology , Liver/pathology , Phylogeny , Polymerase Chain Reaction , Sweden
4.
J Clin Microbiol ; 54(11): 2798-2803, 2016 11.
Article in English | MEDLINE | ID: mdl-27605714

ABSTRACT

In a retrospective multicenter study, 102 formalin-fixed paraffin-embedded (FFPE) tissue specimens with histopathology results were tested. Two 4- to 5-µm FFPE tissue sections from each specimen were digested with proteinase K, followed by automated nucleic acid extraction. Multiple real-time quantitative PCR (qPCR) assays targeting the internal transcribed spacer 2 (ITS2) region of ribosomal DNA, using fluorescently labeled primers, was performed to identify clinically important genera and species of Aspergillus, Fusarium, Scedosporium, and the Mucormycetes The molecular identification was correlated with results from histological examination. One of the main findings of our study was the high sensitivity of the automated DNA extraction method, which was estimated to be 94%. The qPCR procedure that was evaluated identified a range of fungal genera/species, including Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, Aspergillus niger, Fusarium oxysporum, Fusarium solani, Scedosporium apiospermum, Rhizopus oryzae, Rhizopus microsporus, Mucor spp., and Syncephalastrum Fusarium oxysporum and F. solani DNA was amplified from five specimens from patients initially diagnosed by histopathology as having aspergillosis. Aspergillus flavus, S. apiospermum, and Syncephalastrum were detected from histopathological mucormycosis samples. In addition, examination of four samples from patients suspected of having concomitant aspergillosis and mucormycosis infections resulted in the identification of two A. flavus isolates, one Mucor isolate, and only one sample having both R. oryzae and A. flavus Our results indicate that histopathological features of molds may be easily confused in tissue sections. The qPCR assay used in this study is a reliable tool for the rapid and accurate identification of fungal pathogens to the genus and species levels directly from FFPE tissues.


Subject(s)
Aspergillus/isolation & purification , Fusarium/isolation & purification , Mucorales/isolation & purification , Mycoses/diagnosis , Pathology, Molecular/methods , Real-Time Polymerase Chain Reaction/methods , Scedosporium/isolation & purification , Aspergillus/genetics , Automation, Laboratory/methods , DNA, Ribosomal Spacer/chemistry , DNA, Ribosomal Spacer/genetics , Diagnosis, Differential , Disinfectants , Fixatives , Formaldehyde , Fusarium/genetics , Humans , Mucorales/genetics , Paraffin , Scedosporium/genetics , Specimen Handling/methods , Tissue Fixation
5.
J Interferon Cytokine Res ; 36(8): 488-98, 2016 08.
Article in English | MEDLINE | ID: mdl-27142572

ABSTRACT

Invasive aspergillosis is a major threat to patients suffering from impaired neutrophil function, with Aspergillus fumigatus being the most common species causing this life-threatening condition. Patients with chronic granulomatous disease (CGD) not only develop infections with A. fumigatus, but also exhibit a unique susceptibility to infection with the normally nonpathogenic species Aspergillus nidulans. In this study, we compared the inflammatory cytokine response of peripheral blood mononuclear cells (PBMCs) from healthy and CGD patients to these two fungal species. CGD patients displayed evidence for a chronic hyperinflammatory state as indicated by elevated plasma IL-1ß and TNF-α levels. PBMCs isolated from CGD patients secreted higher levels of IL-1ß and TNF-α in response to A. nidulans as compared with A. fumigatus. The presence or absence of melanin in the cell wall of A. nidulans did not alter the cytokine release by healthy or CGD PBMCs. In contrast, A. fumigatus mutants lacking melanin stimulated higher levels of proinflammatory cytokine release from healthy, but not CGD PBMCs. Purified cell wall polysaccharides of A. nidulans induced a much higher level of IL-1ß secretion by CGD PBMCs than did cell wall polysaccharides isolated from A. fumigatus. Using modified A. nidulans strains overexpressing galactosaminogalactan, we were able to show that the increased secretion of inflammatory cytokines by CGD PBMCs in response to A. nidulans are a consequence of low levels of cell wall-associated galactosaminogalactan in this species.


Subject(s)
Aspergillus nidulans/metabolism , Cell Wall/metabolism , Granulomatous Disease, Chronic/microbiology , Host-Pathogen Interactions , Polysaccharides/metabolism , Biomarkers , Case-Control Studies , Cytokines/blood , Cytokines/metabolism , Granulomatous Disease, Chronic/immunology , Granulomatous Disease, Chronic/metabolism , Granulomatous Disease, Chronic/pathology , Humans , Inflammation Mediators/blood , Inflammation Mediators/metabolism , Interleukin-1beta/metabolism , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Melanins/metabolism , Melanins/pharmacology
6.
Fungal Genet Biol ; 82: 129-35, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26092193

ABSTRACT

The Aspergillus fumigatus cyp51A gene TR46/Y121F/T289A mutation is a new emerging resistance mechanism with high-level voriconazole (VOR) resistance, and elevated MICs to all other medical azoles. This is highly worrisome as VOR is the primary drug for the treatment of many aspergillus diseases. The 46 base pair tandem repeat (TR46) is positioned at the same location of the cyp51A gene promoter region as has been described for other tandem repeats. The exact role of the TR46 in combination with the two amino acid changes (Y121F and T289A) in the CYP51A protein is unknown. In this study this azole resistance mechanism was investigated by recombinant analysis study combined with homology modelling. MICs of the TR46/Y121F/T289A recombinant corresponded to the MICs of the original clinical isolates containing the same mutations with high-level resistance to VOR. The TR46 or Y121F by itself has only a moderate effect on azole susceptibility. The combination of TR46/Y121F, however, appears to be highly resistant not only for VOR but also for itraconazole (ITZ). The genetic change of T289A in combination with TR46 or by itself has no significant effect on the phenotype but moderates the phenotype of the ITZ resistance only in the presence of Y121F. The striking resistant phenotype of the TR46/Y121F mutant is supported by the structural analysis of the CYP51A homology model. The A. fumigatus CYP51A Y121 residue forms an H-bond with the heme centre of the enzyme. Disruption of the H-bond by the Y121F substitution destabilizes the active centre of CYP51A which appears to be essential with respect to azole resistance. In CYP51A-azole complexes, residue T289 is in close proximity of the azole moiety of VOR. Replacement of the polar amino acid threonine by the more hydrophobic amino acid alanine might promote more stable drug-protein interactions and has thereby an impact on ITZ susceptibility, which is confirmed by the MICs of the genetic recombinants.


Subject(s)
Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Azoles/pharmacology , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal , Fungal Proteins/genetics , Genotype , Mutation , Phenotype , Amino Acid Sequence , Amino Acid Substitution , Antifungal Agents/pharmacology , Cytochrome P-450 Enzyme System/chemistry , Fungal Proteins/chemistry , Gene Expression , Genetic Association Studies , Microbial Sensitivity Tests , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Protein Conformation , Sequence Alignment , Structure-Activity Relationship
7.
J Clin Microbiol ; 53(7): 2343-5, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25903576

ABSTRACT

High-level pan-azole-resistant Aspergillus fumigatus was recovered from four patients with chronic lung disease. In one patient, the development of progressive resistance followed long-term azole therapy and switching between antifungal azoles. The high-level pan-azole-resistant phenotypes were not associated with a specific cyp51A gene mutation. New strategies that avoid the development of progressive azole resistance are needed.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/isolation & purification , Azoles/pharmacology , Pulmonary Aspergillosis/microbiology , Adult , Aged , Cytochrome P-450 Enzyme System/genetics , Female , Fungal Proteins/genetics , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Mutation , Young Adult
8.
J Infect Dis ; 207(12): 1932-9, 2013 Jun 15.
Article in English | MEDLINE | ID: mdl-23482646

ABSTRACT

Invasive aspergillosis is a major threat to patients with chronic granulomatous disease (CGD). Fungal pathogenesis is the result of a diminished antifungal capacity and dysregulated inflammation. A deficient NADPH-oxidase complex results in defective phagolysosomal alkalization. To investigate the contribution of defective pH regulation in phagocytes among patients with CGD during fungal pathogenesis, we evaluated the effect of the acidotropic, antimalarial drug chloroquine (CQ) on the antifungal capacity of polymorphonuclear cells (PMNs) and on the inflammatory response of peripheral blood mononuclear cells (PBMCs). Chloroquine exerted a direct pH-dependent antifungal effect on Aspergillus fumigatus and Aspergillus nidulans; it increased the antifungal activity of PMNs from patients with CGD at a significantly lower concentration, compared with the concentration for PMNs from healthy individuals; and decreased the hyperinflammatory state of PBMCs from patients with CGD, as observed by decreased tumor necrosis factor α and interleukin 1ß release. Chloroquine targets both limbs of fungal pathogenesis and might be of great value in the clearance of invasive aspergillosis in patients with CGD.


Subject(s)
Aspergillosis/immunology , Aspergillus fumigatus/immunology , Aspergillus nidulans/immunology , Chloroquine/pharmacology , Granulomatous Disease, Chronic/microbiology , Phagocytes/immunology , Antifungal Agents/pharmacology , Antimalarials/pharmacology , Aspergillosis/complications , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Aspergillus nidulans/drug effects , Cytokines/metabolism , Dose-Response Relationship, Drug , Granulomatous Disease, Chronic/complications , Granulomatous Disease, Chronic/immunology , Humans , Hydrogen-Ion Concentration , Membrane Glycoproteins/deficiency , Membrane Glycoproteins/genetics , NADPH Oxidase 2 , NADPH Oxidases/deficiency , NADPH Oxidases/genetics , Phagocytes/drug effects , Phagocytes/microbiology , Phagosomes/drug effects , Phagosomes/immunology , Phagosomes/microbiology
9.
J Antimicrob Chemother ; 68(2): 385-93, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23129729

ABSTRACT

OBJECTIVES: Azole resistance is an emerging problem in the treatment of Aspergillus fumigatus infections. Combination therapy may be an alternative approach to improve therapeutic outcome in azole-resistant invasive aspergillosis (IA). The in vivo efficacy of voriconazole and anidulafungin was investigated in a non-neutropenic murine model of IA using voriconazole-susceptible and voriconazole-resistant A. fumigatus clinical isolates. METHODS: Treatment groups consisted of voriconazole monotherapy, anidulafungin monotherapy and voriconazole + anidulafungin at 2.5, 5, 10 and 20 mg/kg body weight/day for 7 consecutive days. In vitro and in vivo drug interactions were analysed by non-parametric Bliss independence and non-linear regression analysis. RESULTS: Synergistic interaction between voriconazole and anidulafungin against the voriconazole-susceptible isolate (AZN 8196) was observed in vitro and in vivo. However, among animals infected with the voriconazole-resistant isolate (V 52-35), 100% survival was observed only in groups receiving the highest doses (20 mg/kg voriconazole + 20 mg/kg anidulafungin). For this isolate, additivity, but not synergy, was observed in vivo. CONCLUSIONS: Combination of voriconazole and anidulafungin was synergistic in voriconazole-susceptible IA, but additive in voriconazole-resistant IA. There is a clear benefit of combining voriconazole and anidulafungin, but the reduced effect of combination therapy in azole-resistant IA raises some concern.


Subject(s)
Antifungal Agents/administration & dosage , Aspergillosis/drug therapy , Drug Resistance, Fungal , Echinocandins/administration & dosage , Pyrimidines/administration & dosage , Triazoles/administration & dosage , Anidulafungin , Animals , Antifungal Agents/pharmacokinetics , Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Disease Models, Animal , Drug Synergism , Drug Therapy, Combination/methods , Echinocandins/pharmacokinetics , Echinocandins/pharmacology , Female , Mice , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Survival Analysis , Treatment Outcome , Triazoles/pharmacokinetics , Triazoles/pharmacology , Voriconazole
10.
Antimicrob Agents Chemother ; 57(2): 796-803, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23183435

ABSTRACT

Voriconazole is the recommended drug of first choice to treat infections caused by Aspergillus fumigatus. The efficacy of voriconazole might be hampered by the emergence of azole resistance. However, the combination of voriconazole with anidulafungin could improve therapeutic outcomes in azole-resistant invasive aspergillosis (IA). The in vitro interaction between voriconazole and anidulafungin was determined against voriconazole-susceptible and voriconazole-resistant (substitutions in the cyp51A gene, including single point [M220I and G54W] and tandem repeat [34-bp tandem repeat in the promoter region of the cyp51A gene in combination with substitutions at codon L98 and 46-bp tandem repeat in the promoter region of the cyp51A gene in combination with mutation at codons Y121 and T289] mutations) clinical A. fumigatus isolates using a checkerboard microdilution method with spectrophotometric analysis and a viability-based XTT {2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide} assay within 2 h of exposure after 24 and 48 h of incubation at 35 °C to 37 °C. Fractional inhibitory concentration (FIC) indexes (FICis) were determined using different MIC endpoints and Bliss independence analysis performed based on the response surface calculation of the no-drug interaction. Significant synergistic interactions obtained based on measuring the FIC index were dependent on the MIC endpoint, in which FICs were inversely related to voriconazole and anidulafungin MICs and were influenced by the CYP51A genotype. A statistically significant difference was observed between FIC indexes of isolates harboring tandem repeat mutations and wild-type controls (P = 0.006 by one-way analysis of variance [ANOVA]), indicating that synergy is decreased in azole-resistant strains. Our results indicated that a combination of voriconazole and anidulafungin might be effective against infections caused by both azole-susceptible and azole-resistant A. fumigatus isolates, but the combination could possibly be less effective in voriconazole-resistant strains with high MICs. Studies in vivo and in vitro-in vivo correlation investigations are required to validate the potential synergy of voriconazole and anidulafungin.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Echinocandins/pharmacology , Pyrimidines/pharmacology , Triazoles/pharmacology , Anidulafungin , Aspergillus fumigatus/genetics , Aspergillus fumigatus/isolation & purification , Cytochrome P-450 Enzyme System/genetics , Drug Interactions , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Microbial Sensitivity Tests , Point Mutation/genetics , Promoter Regions, Genetic/genetics , Tandem Repeat Sequences/genetics , Voriconazole
11.
PLoS One ; 7(11): e50034, 2012.
Article in English | MEDLINE | ID: mdl-23226235

ABSTRACT

Azole compounds are the primary therapy for patients with diseases caused by Aspergillus fumigatus. However, prolonged treatment may cause resistance to develop, which is associated with treatment failure. The azole target cyp51A is a hotspot for mutations that confer phenotypic resistance, but in an increasing number of resistant isolates the underlying mechanism remains unknown. Here, we report the discovery of a novel resistance mechanism, caused by a mutation in the CCAAT-binding transcription factor complex subunit HapE. From one patient, four A. fumigatus isolates were serially collected. The last two isolates developed an azole resistant phenotype during prolonged azole therapy. Because the resistant isolates contained a wild type cyp51A gene and the isolates were isogenic, the complete genomes of the last susceptible isolate and the first resistant isolate (taken 17 weeks apart) were sequenced using Illumina technology to identify the resistance conferring mutation. By comparing the genome sequences to each other as well as to two A. fumigatus reference genomes, several potential non-synonymous mutations in protein-coding regions were identified, six of which could be confirmed by PCR and Sanger sequencing. Subsequent sexual crossing experiments showed that resistant progeny always contained a P88L substitution in HapE, while the presence of the other five mutations did not correlate with resistance in the progeny. Cloning the mutated hapE gene into the azole susceptible akuB(KU80) strain showed that the HapE P88L mutation by itself could confer the resistant phenotype. This is the first time that whole genome sequencing and sexual crossing strategies have been used to find the genetic basis of a trait of interest in A. fumigatus. The discovery may help understand alternate pathways for azole resistance in A. fumigatus with implications for the molecular diagnosis of resistance and drug discovery.


Subject(s)
Aspergillosis/drug therapy , Aspergillus fumigatus/genetics , Azoles/pharmacology , CCAAT-Binding Factor/genetics , Drug Resistance, Fungal/genetics , Genome, Fungal , Mutation , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/isolation & purification , Azoles/therapeutic use , Cloning, Molecular , Crosses, Genetic , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal/drug effects , Fungal Proteins/genetics , Humans , Microbial Sensitivity Tests , Protein Isoforms/genetics , Sequence Analysis, DNA
12.
J Clin Microbiol ; 50(8): 2674-80, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22675126

ABSTRACT

A rapid emergence of azole resistance has been observed in Aspergillus fumigatus in The Netherlands over the past decade. The dominant resistance mechanism appears to be of environmental origin and involves the TR(34)/L98H mutations in cyp51A. This resistance mechanism is now also increasingly being found in other countries. Therefore, genetic markers were used to gain more insights into the origin and spread of this genotype. Studies of 142 European isolates revealed that those with the TR(34)/L98H resistance mechanism showed less genetic variation than azole-susceptible isolates or those with a different genetic basis of resistance and were assigned to only four CSP (putative cell surface protein) types. Sexual crossing experiments demonstrated that TR(34)/L98H isolates could outcross with azole-susceptible isolates of different genetic backgrounds, suggesting that TR(34)/L98H isolates can undergo the sexual cycle in nature. Overall, our findings suggest a common ancestor of the TR(34)/L98H mechanism and subsequent migration of isolates harboring TR(34)/L98H across Europe.


Subject(s)
Antifungal Agents/pharmacology , Aspergillosis/epidemiology , Aspergillus fumigatus/classification , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal , Fungal Proteins/genetics , Aspergillosis/microbiology , Aspergillus fumigatus/genetics , Aspergillus fumigatus/isolation & purification , Crosses, Genetic , DNA, Fungal/chemistry , DNA, Fungal/genetics , Europe/epidemiology , Genetic Variation , Humans , Microbial Sensitivity Tests , Molecular Epidemiology , Mutation , Recombination, Genetic , Sequence Analysis, DNA
13.
BMC Microbiol ; 8: 135, 2008 Aug 12.
Article in English | MEDLINE | ID: mdl-18694525

ABSTRACT

BACKGROUND: In Tanzania, little is known on the species distribution and antifungal susceptibility profiles of yeast isolates from HIV-infected patients with primary and recurrent oropharyngeal candidiasis. METHODS: A total of 296 clinical oral yeasts were isolated from 292 HIV-infected patients with oropharyngeal candidiasis at the Muhimbili National Hospital, Dar es Salaam, Tanzania. Identification of the yeasts was performed using standard phenotypic methods. Antifungal susceptibility to fluconazole, itraconazole, miconazole, clotrimazole, amphotericin B and nystatin was assessed using a broth microdilution format according to the guidelines of the Clinical and Laboratory Standard Institute (CLSI; M27-A2). RESULTS: Candida albicans was the most frequently isolated species from 250 (84.5%) patients followed by C. glabrata from 20 (6.8%) patients, and C. krusei from 10 (3.4%) patients. There was no observed significant difference in species distribution between patients with primary and recurrent oropharyngeal candidiasis, but isolates cultured from patients previously treated were significantly less susceptible to the azole compounds compared to those cultured from antifungal naïve patients. CONCLUSION: C. albicans was the most frequently isolated species from patients with oropharyngeal candidiasis. Oral yeast isolates from Tanzania had high level susceptibility to the antifungal agents tested. Recurrent oropharyngeal candidiasis and previous antifungal therapy significantly correlated with reduced susceptibility to azoles antifungal agents.


Subject(s)
AIDS-Related Opportunistic Infections/microbiology , Antifungal Agents/pharmacology , Candidiasis, Oral/microbiology , Oropharynx/microbiology , Yeasts/drug effects , Yeasts/isolation & purification , AIDS-Related Opportunistic Infections/drug therapy , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/pathology , Adult , Candida albicans/drug effects , Candida albicans/isolation & purification , Candidiasis, Oral/epidemiology , Candidiasis, Oral/pathology , Female , Humans , Male , Microbial Sensitivity Tests , Recurrence , Tanzania/epidemiology
14.
Emerg Infect Dis ; 14(4): 566-72, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18394273

ABSTRACT

We noted a cluster of 4 cases of infection or colonization by Emericella spp., identified by sequence-based analysis as E. quadrilineata. Sequence-based analysis of an international collection of 33 Emericella isolates identified 12 as E. nidulans, all 12 of which had previously been identified by morphologic methods as E. nidulans. For 12 isolates classified as E. quadrilineata, only 6 had been previously identified accordingly. E. nidulans was less susceptible than E. quadrilineata to amphotericin B (median MICs 2.5 and 0.5 mg/L, respectively, p<0.05); E. quadrilineata was less susceptible than E. nidulans to caspofungin (median MICs, 1.83 and 0.32 mg/L, respectively, p<0.05). These data indicate that sequence-based identification is more accurate than morphologic examination for identifying Emericella spp. and that correct species demarcation and in vitro susceptibility testing may affect patient management.


Subject(s)
Emericella/isolation & purification , Mycoses/microbiology , Adult , Antifungal Agents/pharmacology , Aspergillosis/microbiology , Base Composition , Child , DNA, Fungal , DNA, Intergenic/genetics , Emericella/classification , Emericella/drug effects , Emericella/genetics , Female , Humans , Male , Middle Aged , Phylogeny
15.
Clin Infect Dis ; 43(3): e23-5, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16804836

ABSTRACT

A paradoxical increase in circulating Aspergillus antigen was observed during treatment with caspofungin in a patient with proven invasive aspergillosis. With the exception of treatment with the echinocandin, no other factors were found that might explain this clinical observation, which was supported by experiments done in vitro.


Subject(s)
Antifungal Agents/therapeutic use , Antigens, Fungal/blood , Aspergillosis/drug therapy , Aspergillus fumigatus/immunology , Lung Diseases, Fungal/drug therapy , Peptides, Cyclic/therapeutic use , Adult , Aspergillosis/immunology , Caspofungin , Echinocandins , Fungal Proteins/therapeutic use , Hematopoietic Stem Cell Transplantation , Humans , Immunocompromised Host , Immunosuppressive Agents/therapeutic use , Lipopeptides , Lung Diseases, Fungal/immunology , Male , Myelodysplastic Syndromes/therapy
16.
Med Mycol ; 44(4): 379-82, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16772234

ABSTRACT

A male renal transplant patient developed a tumor on the dorsum of his right hand. After excision, histological examination of the tumor showed hyphal structures, but growth developed very slowly. Therapy consisted of surgery alone. A definitive identification of Alternaria infectoria was only possible with molecular techniques.


Subject(s)
Alternaria/classification , Alternaria/isolation & purification , Dermatomycoses/diagnosis , Dermatomycoses/microbiology , Kidney Transplantation/adverse effects , Alternaria/drug effects , Alternaria/genetics , Antifungal Agents/pharmacology , Dermatomycoses/surgery , Humans , Male , Middle Aged , Molecular Sequence Data , Opportunistic Infections/diagnosis , Opportunistic Infections/microbiology , Opportunistic Infections/surgery
17.
Clin Infect Dis ; 40(12): e110-2, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15909252

ABSTRACT

A case of invasive Fusarium keratitis in a previously healthy male patient was treated successfully with cornea transplantation and systemic and topical voriconazole after treatment failure with topical amphotericin B and systemic itraconazole. Topical voriconazole was well tolerated, and, in conjunction with the oral administration, it resulted in a high level of the drug in the anterior chamber of the eye (which was 160% of the plasma drug level).


Subject(s)
Corneal Transplantation , Fusarium/isolation & purification , Keratitis/microbiology , Keratitis/therapy , Mycoses/drug therapy , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Adult , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Cornea/pathology , Humans , Itraconazole/therapeutic use , Male , Mycoses/microbiology , Voriconazole
18.
J Clin Microbiol ; 41(5): 2261-4, 2003 May.
Article in English | MEDLINE | ID: mdl-12734297

ABSTRACT

A case of Scedosporium apiospermum keratitis was successfully treated with oral voriconazole and penetrating keratoplasty. Voriconazole levels in the aqueous humor were 53% of the levels in plasma and exceeded the MIC for the isolate by sevenfold.


Subject(s)
Antifungal Agents/therapeutic use , Ascomycota/pathogenicity , Corneal Ulcer/drug therapy , Corneal Ulcer/microbiology , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Ascomycota/drug effects , Ascomycota/isolation & purification , Corneal Transplantation , Corneal Ulcer/surgery , Humans , Keratoplasty, Penetrating , Male , Middle Aged , Voriconazole
SELECTION OF CITATIONS
SEARCH DETAIL
...